GlassScriptPhysician profile
Zachary Logan
NPI 1538521620
$6,084.16
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $953 · 2021: $1,410 · 2022: $2,848 · 2023: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $612 · Food and Beverage: $31.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $612.31 |
| Food and Beverage | $31.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $2,713.15 | 2022-2023 | Legacy Stelkast Knee |
| Novo Nordisk INC | $540.74 | 2019-2022 | |
| Abbvie INC. | $469.28 | 2021-2023 | |
| Glaxosmithkline, LLC. | $371.95 | 2019-2022 | |
| Amarin Pharma, INC. | $337.70 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.60 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $184.63 | 2019-2022 | |
| Pfizer INC. | $160.76 | 2019-2022 | |
| Lilly USA, LLC | $147.32 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $122.34 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.86 | 2021-2022 | |
| Allergan, INC. | $94.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.07 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $67.91 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.40 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $42.07 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $40.87 | 2019-2020 | |
| Amgen INC. | $32.04 | 2019-2022 | |
| Medtronic, INC. | $30.28 | 2021 | |
| Arbor Pharmaceuticals, INC. | $27.96 | 2021 | |
| Astellas Pharma US INC | $27.06 | 2021 | |
| Phadia US INC. | $21.08 | 2022 | |
| Pacira Therapeutics, INC. | $18.66 | 2019 | |
| Esperion Therapeutics, INC. | $17.72 | 2021 | |
| Exact Sciences Corporation | $16.79 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $16.41 | 2022 | |
| Eisai INC. | $16.28 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.54 | 2022 | |
| Merck Sharp & Dohme LLC | $14.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.81 | 2022 | |
| Daiichi Sankyo INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Logan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.